Clinigen Group synergy provides lifeline to patients

For Clinigen Group, paving the way for greater availability of medical provisions is one step towards improving global health. Clinigen Group works ceaselessly throughout a drug's clinical lifecycle to ensure that patients always have access to effective medications.

"Our goal is not to promote a type of medicine," says group CEO Peter George. "It's about having drugs that are very effective in their treatment areas and guaranteeing their availability."

The Clinigen Group comprises three entities working synergistically with each other: Clinigen Clinical Trials Supply (CTS), Clinigen Specialty Pharmaceuticals (SP) and Clinigen Global Access Programme (GAP).

Clinigen CTS is a crucial link in the clinical trials stage of a drug. Functioning as a contact point between medicine manufacturers, contract research firms and clinical trial contract packagers, CTS scours the globe for the right drugs for the clinical trial patients.

CTS has notable partnerships in mature and emerging markets.

It has worked with the China Food and Drug Administration to ship products to trial sites in the United States. CTS has also collaborated with Accord Healthcare, distributing the latter's injectable cancer drugs across clinical trial sites in the European Union.